Neurocrine Biosciences (NBIX) Property, Plant & Equipment (Net) Growth (3y) (2013 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Property, Plant & Equipment (Net) Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PP&E (Net) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.24 Bn | 623.49 Bn | 17.26 Bn | 4.65% |
| 2 | AbbVie | 443.24 Bn | 436.67 Bn | 12.70 Bn | 5.45% |
| 3 | Merck | 364.92 Bn | 357.78 Bn | 12.21 Bn | 5.00% |
| 4 | Novartis Ag | 266.33 Bn | 258.64 Bn | 11.24 Bn | -0.43% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.85% |
| 6 | Sanofi | 52.37 Bn | 44.99 Bn | 10.79 Bn | 3.06% |
| 7 | Revolution Medicines | 44.03 Bn | 44.03 Bn | - | - |
| 8 | Incyte | 25.35 Bn | 20.82 Bn | 1.57 Bn | -1.81% |
| 9 | United Therapeutics | 21.58 Bn | 18.92 Bn | 683.80 Mn | 27.15% |
| 10 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 11.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.32% |
| Mar 31, 2026 | 13.12% |
| Dec 31, 2025 | 15.29% |
| Sep 30, 2025 | 16.90% |
| Jun 30, 2025 | 11.14% |
| Mar 31, 2025 | 10.83% |
| Dec 31, 2024 | 12.12% |
| Sep 30, 2024 | 16.12% |
| Jun 30, 2024 | 17.01% |
| Mar 31, 2024 | 18.46% |
| Dec 31, 2023 | 16.65% |
| Sep 30, 2023 | 16.96% |
| Jun 30, 2023 | 13.73% |
| Mar 31, 2023 | 14.44% |
| Dec 31, 2022 | 11.83% |
| Sep 30, 2022 | 14.75% |
| Jun 30, 2022 | 19.02% |
| Mar 31, 2022 | 20.35% |
| Dec 31, 2021 | 20.05% |
| Sep 30, 2021 | 21.32% |